Regorafenib,Ipilimumab,Nivolumab
bms,bayer
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'nivo', 'nivolumab', ' 320mo', 'regorafenib', 'ipilimumab']
interesting mini oral presentation at #esmo2022! a phase i clinical trial of #regorafenib, #ipilimumab, and #nivolumab #rin in chemotherapy resistant #mss #mcrc! 12/09/2022, 14:45 mini oral session: gi, lower digestive, 320mo #meded 
Independent and international experts in GI oncology supporting medical oncologists to give the best possible care to patients. Part of https://t.co/Y8pV8OaxOB